Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ga-68-PSMA-11 PET/CT in High-Risk Prostate Cancer
NCT03362359Phase 2Completed
- Sponsor
- German Cancer Research Center
- Start
- Oct 2017
- Primary completion
- Jul 2020
- Modality
- Peptide-Drug Conjugates
- Countries
- 2
01
Overview
Phase 2, single-blind, single-arm trial of gallium ga-68 gozetotide in prostate cancer (PCa), sponsored by German Cancer Research Center. Primary endpoints: True positive fraction (TPF) and false positive fraction (FPF) of identified tumour tissue at Day 21 and Frequency of occurrence and severity of abnormal findings in safety investigations. Started Oct 2017; status: completed.
02
Drugs
gallium ga-68 gozetotide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03362359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03362359.